Neuroimaging diagnosis in neurodegenerative diseases

Nuclear Medicine Review

Volumn 13, Issue 1, 2010, Pages 23-31

  Szymański, Pawet ^a   Markowicz, Magdalena ^a   Janik, Agnieszka ^a   Ciesielski, Mateusz ^a   Mikiciuk Olasik, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Central nervous system; Neurodegenerative disease; Neuroimaging

Indexed keywords

6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALTROPANE; AMYLOID BETA PROTEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBON 11; COBALT 57; COCAINE; CYSTEINE ETHYL ESTER TC 99M; DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; ECGONINE METHYL ESTER; FLORBETABEN; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INOSITOL; IODINE 123; IOFETAMINE I 123; IOFLUPANE I 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N ACETYLASPARTIC ACID; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NOMIFENSINE; PHENETHYLAMINE; RACLOPRIDE C 11; RADIOLIGAND; TRACER; TROPANE DERIVATIVE; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN BLOOD FLOW; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FUNCTIONAL ASSESSMENT; GLUCOSE METABOLISM; HUMAN; HUNTINGTON DISEASE LIKE SYNDROME; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL MUSCULAR ATROPHY;

BRAIN; DIAGNOSTIC IMAGING; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 78650746218     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. American Academy of Neurology. Neurology 2006; 66: 968-975.
2. Brooks D. Imaging studies in drug development: Parkinson's disease. Drug Discov Today: Technologies 2005; 2: 317-321.
3. Siderowf A, Stern M. Update on Parkinson disease. Annals of Internal Med 2003; 8: 651-658.
4. 99mTc-TRODAT-1 imaging. J Nucl Med 2001; 9: 1303-1308.
5. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies In Parkinsonian syndromes: from the lesion to its consequences. Neurolmage 2004; 23: 1-16.
6. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
7. Seibyl J, Chen W, Silverman D. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Nucl Med 2008; 03: 274-286.
8. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol 2006; 5: 796-802.
9. Seibyl JR Imaging studies in movement disorders. Seminars in Nucl Med 2003; 2: 105-113.
10. Samii A, Nutt J G, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-93.
11. Brooks D. Neuroimaging in Parkinson's disease. NeuroRx 2004; 1: 243-254.
12. Nobili F, Brugnolo A, Calvini P et al. Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clin Neurophysiol 2005; 116: 364-375.
13. Antonini A, DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med 2004; 5: 201-206.
14. Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005; 2: 361-371.
15. Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol 2004; 3: 284-290.
16. 18F]-Fluoro-L- Phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Nucl Med 2007; 08: 440-450.
17. S. Thobois S, Guillouet E, Broussolle. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin 2001; 31: 321-340.
18. Small GW, Bookheimer S, Thompson PM. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7: 161-72.
19. Killiany R, Hyman B, Gomez-Isla T et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002; 58: 1188-1196.
20. Brookes D J. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Am Soc for Experimental NeuroTherapeutics 2005; 2: 226-236.
21. 18F]Fluoro-D-Glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 2002; 4: 283-293.
22. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007; 6: 926-32.
23. 18F]2-Ftuoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000; 24: 18489-18494.
24. Smith D. Imaging the progression of Alzheimer pathology through the brain. PNAS 2002; 7: 4135-4137.
25. Petrella J, Coleman E, Doraiswamy P. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003; 226: 315-336.
26. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
27. Waragai M, Okamura N, Furukawa N et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci 2009; 285: 100-108.
28. Honson NS, Johnson RL, Huang W, Inglese J, Austin CR Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 2007; 28: 251-260.
29. 18F]Fluoro-D-Glucose positron emission tomography in Alzheimer's diagnosis: time for technology transfer. Molecular Imaging and Biology 2003; 6: 385-386.
30. Scahill R, Shott MJ, Stevens MJ et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. PNAS 2002; 7: 4703-4707.
31. Small GW, Bookheimer S, Thompson PM. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7: 161-72.
32. Rombouts S, Barkhof F, Veltman DJ et al. Functional MR imaging in Alzheimer's disease during memory encoding. Am J Neuroradiol 2000; 21: 1869-1875.
33. O'Brien J, Barber B. Neuroimaging in dementia and depression. Adv Psych Treat 2000; 6: 109-119.
34. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009; 35: 128-140.
35. McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 2000; 217: 58-68.
36. Garrido G, Furuie SS, Buchpiguel CA. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry 2002; 73: 508-516.
37. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx 2004; 1: 206-212.
38. Jagust W, Thisted R, Devous MD et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease. Neurology 2001; 56: 950-956.
39. Coleman ER, Dillehay GL, Gelfand MJ et al. ACR Practice guideline for the performance of single photon emission computed tomography (SPECT) brain perfusion imaging. Spect Brain Perfusion Imaging 2002; 19: 429-433.
40. Wu C, Wei J, Gao K, Wang Y Dibenzothiazoles as novel amyloid-imaging agents. Bioorgan Med Chem 2007; 15: 2789-2796.
41. 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004; 45: 594-607.
42. Camargo E. Brain SPECT in neurology and psychiatry. Nucl Med 2001 ; 42: 611-623.
43. Sonnen J, Montine K, Quinn J et al. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008; 7: 704-714.
44. Masdeua JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005; 236: 55-64.
45. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med 2003; 3: 1-4.
46. Klimas MT. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol Imaging Biol 2002; 5: 311-337.
47. Small GW. Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease. Adv Drug Deliver Rev 2002; 54: 1561-1566.
48. 99mTc-ECD SPECT, MRI and neuropsychological testing in senile dementia of the Alzheimer type. Nucl Med Commun 2001 ; 22: 713-719.
49. Schipper HM. The role of biologic markers in the diagnosis of Alzheimer's disease. Alzheimers Dement 2007; 3: 325-332.
50. Sjogren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease -use of cerebrospinal fluid biomarkers. Clin Chim Acta 2003; 332: 1-10.
51. Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and A 1-42 proteins to phosphorylated tau protein. Brain Res Bull 2003; 61: 243-253.
52. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007; 34: 809-822.
53. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613.
54. Blennow K, Vanmechelen E. CSF markers for pathogenic processes In Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003; 61: 235-242.
55. Shi M, Caudle WM, Hang J. Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiol Dis 2009; 35: 157-164.
56. Boss M A. Diagnostic approaches to Alzheimer's disease. Biochim Biophys Acta 2000; 1502: 188-200.
57. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med 2001 ; 4: 296-311.
58. Kulkarni PV, Arora V, Roney AC et al. Radiolabeled probes for imaging Alzheimer's plaques. Nucl Instrum B 2005; 241: 676-680.
59. Wu C, Wei J, Gao K, Wang Y Dibenzothiazoles as novel amyloid-imaging agents. Bioorgan Med Chem 2007; 15: 2789-2796.
60. 18F-Labeled 6-lodo-2-(4c-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for â-amyloid in Alzheimer's disease. J Med Chem 2004; 4: 2208-2218.
61. Andrews TC, Brooks DJ. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET Mol Med Today 1998; 532-539
62. Ross CA, Margolis RL. Huntington's disease. Clin Neurosci Res 2001; 1: 142-152.
63. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008; 58: 209-225.
64. Newberg AB, Alavi A. The study of neurological disorders using positron emission tomography and single photon emission computed tomography. J Neurol Sci 1996; 135: 91-108.
65. Klöppel S, Henley SM, Hobbs NZ et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience 2009; 164: 205-219.
66. Walker FO. Huntington's disease. Lancet 2007; 369: 218-228.
67. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol 2009; 216: 272-277.
68. Miller JC, Thrall JH. Clinical molecular imaging. J Am Coll Radiol 2004; 1: 4-23.
69. Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009; 70: 205-211.
70. Tai YF, Pavese N, Gerhard A et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72: 148-151.
71. Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett 1998; 240: 171-173.
72. 11C] flumazenil. Brain 2000; 123: 2298-2296.
73. Pradhan S, Yadav R, Mishra VN, Aurangabadkar K, Sawlani V. Amyotrophic lateral sclerosis with predominant pyramidal signs -early diagnosis by magnetic resonance imaging. Magn Reson Imaging 2006; 24: 173-179.
74. Hashimoto T, Ohnari K, Hashimoto T et al. Assessment of the neurophysiologic examination in the earlier diagnosis of amyotrophic lateral sclerosis, Int Congr Ser 2005; 1278: 447-450.
75. Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160: 6-24.
76. Karitzky J, Ludolph AC. Imaging and neurochemical markers for diagnosis and disease progression in ALS. J Neurol Sci 2001; 191: 35-41.
77. Waragai M, Hamada T, Matsuda H. Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 2007; 260: 57-64.
78. Kalra S, Arnold DL, Cashman NL. Biological markers in the diagnosis and treatment of ALS. J Neurol Sci 1999; 165: 27-32.
79. 11C] (R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15: 601-609.
80. Vogels OMJ, Veltman J, Oyen WJG, Horstink MWI. Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor down-regulation versus striatal cell degeneration. J Neurol Sci 2000; 180: 62-65.
81. Petri S, Kollewe K, Grothe C et al. GABAA-receptor mRNA expression in the prefrontal and temporal cortex of ALS patients. J Neurol Sci 2006; 250: 124-132.
82. Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Therapeut 2003; 98: 379-414.
83. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci 2007; 259: 21-26.
84. Tumani H, Hartung H-P, Hemmer B et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009; 35: 117-127.
85. Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. Journal of the American Society for Experimental NeuroTherapeutics 2005; 2: 277-303.
86. Sørensen PS, Jonsson A, Mathiesen HK et al. The relationship between MRI and PET changes and cognitive disturbances in MS. J Neurol Sci 2006; 245: 99-102.
87. 99mMIBI brain SPECT in diagnosis of multiple sclerosis acute phase. J Neurol Sci 1997; 150: 329.
88. Tsirikos A, Baker A. Spinal muscular atrophy: Classification, aetiology, and treatment of spinal deformity in children and adolescents. Curr Orthopaed 2006; 20: 430-445.
89. Sumer CJ. Therapeutics development for spinal muscular atrophy. NeuroRx-: The Journal of the American Society for Experimental NeuroTherapeutics 2006; 3: 235-245.
90. Oka A, Matsushita Y, Sakakihara Y, Momose, T Yanaginasawa M. Spinal muscular atrophy with oculomotor palsy, epilepsy and cerebral hypoperfusion. Pediatr Neurol 1995; 12: 365-369.